Kineta (KA.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $281,000 and an expected value of $300,000; earnings per share was -0.89 US dollars, previous value was -0.77 US dollars, and the expected value was -0.21 US dol
Kineta (KA.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $281,000 and an expected value of $300,000; earnings per share was -0.89 US dollars, previous value was -0.77 US dollars, and the expected value was -0.21 US dollars.
Kineta | 10-Q: Quarterly report
Kineta Q1 EPS $(0.89) Misses $(0.21) Estimate
Kineta (NASDAQ:KA) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.21) by 323.81 percent. This is a 15.58 percent decrease over losses of $(0.77) per
Kineta 1Q Rev $0.00 >KA
Kineta 1Q Rev $0.00 >KA
Kineta 1Q Loss/Shr 89c >KA
Kineta 1Q Loss/Shr 89c >KA
Kineta Says Actively Exploring Strategic Alternatives To Maximize Value For All Stakeholders
Kineta Says Actively Exploring Strategic Alternatives To Maximize Value For All Stakeholders
Press Release: Kineta Reports First Quarter 2024 Financial Results and Provides Update on Its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities Partial response and stable disease reported in comb
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Wang & Lee Group, Inc. (NASDAQ:WLGS) rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 financial results.Wang & Lee Group posted a FY23
Kineta Rolls Out New Stock and Cash Incentive Plans
Kineta Granted U.S. Patent Titled 'Proteasome Activity Enhancing Compounds (Including Methods for Treating Cancer or Tumors)'
Kineta Granted U.S. Patent Titled 'Proteasome Activity Enhancing Compounds (Including Methods for Treating Cancer or Tumors)'
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Medical Properties Trust, Inc. (NYSE:MPW) rose sharply in today's pre-market trading after the company announced that it sold its majority interest in Utah Hospitals. Medical Properties Tru
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersIN8bio (NASDAQ:INAB) stock increased by 47.7% to $1.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $69.6 million. Jaguar Health (NASDAQ:JAGX) share
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.
12 Health Care Stocks Moving In Monday's After-Market Session
GainersKineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million. Moleculin Biotech (NASDAQ:MBRX) stoc
Kineta Reports Progress in KVA12123 Cancer Trial
Kineta Reports Favorable Clinical Safety And Tolerability Profile Observed With No Dose Limiting Toxicities And No Evidence Of CRS-Associated Cytokines Observed At Any Dose Level
Kineta Reports Favorable Clinical Safety And Tolerability Profile Observed With No Dose Limiting Toxicities And No Evidence Of CRS-Associated Cytokines Observed At Any Dose Level
Kineta Reports Initial Clinical Response Data At AACR 2024 Of Ongoing Phase 1/2 VISTA-101 Clinical Trial
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsFavorable clinical safety and tolerability profile observed with no dose l
Kineta Reports Initial Clinical Response Data at AACR 2024 of Its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Kineta, Inc. (Nasdaq: KA) announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors.
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
No Data